Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 1 N=9 Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
Primary: Incidence of Pre-specified Infusion Associated Adverse Events — 0; 0; 0 participants
Phase 2 N=136 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Immunosuppresion · Thrombocytopenia · Pancytopenia
Primary: Hematologic Response — 38; 20; 3 Participants
Phase 2 N=21 Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
Chronic Graft-Versus-Host Disease · Immune System Diseases
Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants
Phase 3 N=921 A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Hormone Refractory Prostate Cancer · Bone Metastases
Primary: Overall Survival — 14.9; 11.3 Months — p=0.00005
Phase 3 N=83 TBI Dose De-escalation for Fanconi Anemia
Fanconi Anemia
Primary: Number of Participant With Neutrophil Recovery — 78 Participants
Phase 2 N=30 Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes
Primary: Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) — 30; 25; 10…
Phase 2 N=67 Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
Inflammatory Breast Cancer · Invasive Ductal Breast Carcinoma · Invasive Lobular Breast Carcinoma
Primary: Number of Participants With Local, Regional, and/or Distant Failure — 12 Participants
Phase 2 N=50 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Cancer Other Than Leukemia
Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg
Phase 2 N=42 Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Non-Hodgkin's Lymphoma · Leukemia · Multiple Myeloma
Primary: The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B…
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 2 N=64 RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
Prostate Cancer
Primary: Progression-free Survival — 10.5; 11.8 Months
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
N/A N=12 Effect of High Doses of Radiation on Bone Structure and Metabolism
Malignant Bone Tumors
Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3
Phase 2 N=120 Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) — -0.7; -1.5; 0.8; -1.1 cmH20/mmHg — p=0.34
Phase 2 N=78 All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…